BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
Rhea-AI Summary
BrainsWay (NASDAQ: BWAY) will report its fourth quarter and full year 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. A conference call and webcast will be held at 8:30 AM ET to discuss results and operational highlights.
Dial-in numbers, a webcast link, and a Conference ID are provided; the live broadcast will be available for replay for 30 days on the company investor website.
Positive
- None.
Negative
- None.
News Market Reaction – BWAY
In the Feb 25 session, BWAY gained 0.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference participation | Neutral | +0.0% | Announcement of participation in Citi MedTech and Life Sciences Access Day. |
| Feb 19 | Strategic investment | Positive | -7.5% | Minority-stake equity financing in BrainStim Health with milestone-based tranches. |
| Feb 18 | Coverage policy change | Positive | +4.3% | Evernorth to remove prior authorization for TMS coverage, expanding access. |
| Feb 17 | ADS ratio change | Neutral | +8.6% | Change in ADS-to-ordinary share ratio equivalent to a 2-for-1 ADS split. |
| Jan 21 | Coverage & trial data | Positive | +4.7% | Highmark draft policy for accelerated Deep TMS with strong response/remission data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been operationally positive, with price reactions mostly aligning, except for a negative reaction to the minority-stake investment and a strong positive move on the ADS ratio change.
Over the last few months, BWAY has issued several operational and strategic updates. Coverage developments from Evernorth and Highmark, including expanded access for Deep TMS and an 87.8% response and 78.0% remission rate trial, saw positive price reactions. A strategic minority-stake investment in BrainStim Health coincided with a -7.45% move, while the ADS ratio change, effectively a 2-for-1 ADS split, preceded an 8.61% rise. The upcoming earnings date fits into an active news period with multiple access and structural catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, March 11, 2026 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Israel: | 1-80-921-2373 |
| Conference ID: | 10206784 |
| Webcast: | Link |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
